SlideShare a Scribd company logo
1 of 15
LOGO
Classification (-floxacins)
 First generation FQs
o Norfloxacin
o Ofloxacin
o Pefloxacin
o Ciprofloxacin
Note: Remember as NOP Cipro
 Second generation FQs
o Levofloxacin
o Lomefloxacin
o Moxifloxacin
o Gemifloxacin
o Sparfloxacin
Note: Remember as Levo Lome Moxi Gem Spark
Mechanism of Action
 The FQs enter the bacterium by passive
diffusion through porins in the outer
membrane
 Once inside the cell, they inhibit replication of
bacterial DNA by interfering with the action of
DNA gyrase (Topoisomerase II) and
Topoisomerase IV during bacterial growth and
reproduction
 Topoisomerases are the enzymes that change
the configuration of DNA by a ‘nicking — pass
through — resealing’ mechanism. They do not
change the DNAs primary sequence
Action of type II
DNA
Topoisomerase
Mechanism of Action
 Binding of quinolone to both the enzyme and
the DNA forms a ternary complex that inhibits
the resealing step, and can cause cell death by
inducing the cleavage of the DNA
 Because DNA gyrase is a bacteriospecific target
for anti-microbial therapy, cross resistance with
other, more commonly used anti-microbial
drugs is rare, but this is increasing in the case
of multi-drug resistant organisms
 The second site blocked by FQs– Topoisomerase
IV– is required by bacteria for cell division. It
has been implicated in the process of
In Gram-negative organisms (E.
coli), the inhibition of DNA gyrase
is more significant than that of
Topoisomerase IV, whereas in
Gram-positive organisms
(Streptococci), the opposite is
true.
Mechanism of Action: Flowchart
Uses
 Urinary tract infections:
 High cure rates, even in complicated cases or those with
indwelling catheters or prostatitis
 Chronic Pseudomonas infections respond less completely
 Gonorrhoea:
 Single dose of 500 mg was nearly 100% curative in PPNG as well
as non-PPNG infections, but the cure rates have declined due to
emergence of resistance and it is no longer a first line drug
 Chanchroid:
 500 mg BD for 3 days second line alternative drug to̶̶
Ceftriaxone/ Azithromycin
Uses
 Bacterial gastroenteritis:
 Use is reserved for severe cases of diarrhoea due to EPEC, Shigella, Salmonella,
Campylobacter jejuni infections
 Can reduce stool volume in cholera
 Typhoid:
 One of the 1st choice drugs in typhoid fever
 750 mg BD for 10 days is recommended or 200 mg i.v 12 hourly till oral therapy
can be instituted
 The advantages of Ciprofloxacin are:
o quick defervescence: fever usually subsides in 4-5 days
o Early abetment of symptoms, low incidence of complications and relapse
o Prevention of carrier state due to cidal action
 Ciprofloxacin can be used to treat typhoid carrier (750 mg BD for 4-8 weeks). This
has been found to achieve 92% eradication rate
Uses
 Bone, soft tissue, gynaecological and wound
infections:
 High cure rate have been obtained in osteomyelitis and joint
infections but prolonged treatment with high doses (6-8 weeks
with 750 md BD) is required
 Respiratory infections:
 Not a primary drug because Streptococci and Pneumococci have
low susceptibility
 However, RT infections due to Mycoplasma, Legionella,
H.influenzae respond
 Tuberculosis:
 One of the drugs in multidrug regimens used for resistant TB
 Also useful in atypical mycobacterial infections
Uses
 Gram negative septicaemias:
 Parenteral Ciprofloxacin may be combined with 3rd generation cephalosporin
or an aminoglycoside
 Prophylaxis:
 Prophylactic use for infections in neutropenic or cancer patients and other
susceptible patients
 Conjunctivitis:
 Topical therapy is effective
 Meningitis:
 Though penetration in CSF is not very good, it has been successfully used in
Gram negative bacterial meningitis especially that occuring in
immunocompromised patients or those with CSF shunts
Adverse effects
Fluoroquinolones have good safety record: side
effects occur in ~10% patients, but are
generally mild, withdrawal needed only in 1.5%
 GIT:
 Nausea, vomiting, anorexia, bad taste
 Does not affect gut anaerobes hence diarrhoea is infrequent̶
 CNS:
 Headache, dizziness, restlessness, anxiety, insomnia, impairment
of concentration and dexterity
 Tremor and seizures are rare: occur at high doses or when
predisposing factors are present
Adverse effects
 Skin/hypersensitivity:
 Rash, pruritus, photosensitivity, urticaria, swelling of lips etc.
 Serious cutaneous reactions are rare
 Tendinitis and tendon rupture:
 Risk of tendon damage is higher in patients above 60 yrs age and
in those receiving corticosteroids
 FQs should be stopped at the first sign of tendinitis
Contraindicated during pregnancy
Abbreviations used
 FQs- Fluoroquinolones
 DNA- Deoxyribose Nucleic Acid
 PPNG- Penicillinase Producing Neisseria Gonorrhoeae
 BD- Twice daily
 EPEC- Entero Pathogenic Escherichia Coli
 RT- Respiratory Tract
 TB- Tuberculosis
 CSF- Cerebro Spinal Fluid
 GIT- Gastro Intestinal Tract
 CNS- Central Nervous System
Kingsoft Office

More Related Content

What's hot

Fluoroquinolones
Fluoroquinolones Fluoroquinolones
Fluoroquinolones
VIJAI KUMAR
 
Fluroquinolones 2
Fluroquinolones 2Fluroquinolones 2
Fluroquinolones 2
VIJAI KUMAR
 
Class anti diarrheals
Class anti diarrhealsClass anti diarrheals
Class anti diarrheals
Raghu Prasada
 

What's hot (20)

Fluoroquinolones
Fluoroquinolones Fluoroquinolones
Fluoroquinolones
 
Macrolide antibiotics
Macrolide antibioticsMacrolide antibiotics
Macrolide antibiotics
 
Antibiotics course. 1-Quinolones
Antibiotics course. 1-QuinolonesAntibiotics course. 1-Quinolones
Antibiotics course. 1-Quinolones
 
Aminoglycosides Antibiotic
Aminoglycosides AntibioticAminoglycosides Antibiotic
Aminoglycosides Antibiotic
 
Quinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones PharmacologyQuinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones Pharmacology
 
Antimalarials
AntimalarialsAntimalarials
Antimalarials
 
Quinolones
QuinolonesQuinolones
Quinolones
 
Anti tb drugs
Anti tb drugsAnti tb drugs
Anti tb drugs
 
Fluroquinolones 2
Fluroquinolones 2Fluroquinolones 2
Fluroquinolones 2
 
Cephalosporins
Cephalosporins Cephalosporins
Cephalosporins
 
Cephalosporins & other β lactam antibiotics & cell wall destructors
Cephalosporins & other β lactam  antibiotics & cell wall destructorsCephalosporins & other β lactam  antibiotics & cell wall destructors
Cephalosporins & other β lactam antibiotics & cell wall destructors
 
Macrolides antibiotics (with lincosamide)
Macrolides antibiotics (with lincosamide) Macrolides antibiotics (with lincosamide)
Macrolides antibiotics (with lincosamide)
 
Quinolones
QuinolonesQuinolones
Quinolones
 
Class anti diarrheals
Class anti diarrhealsClass anti diarrheals
Class anti diarrheals
 
Cephalosporins & beta lactams
Cephalosporins & beta lactamsCephalosporins & beta lactams
Cephalosporins & beta lactams
 
Macrolide Antibiotics
Macrolide AntibioticsMacrolide Antibiotics
Macrolide Antibiotics
 
Quinolones and fluoroquinolones
Quinolones and fluoroquinolonesQuinolones and fluoroquinolones
Quinolones and fluoroquinolones
 
Quinolones & Fluoroquinolones
Quinolones & FluoroquinolonesQuinolones & Fluoroquinolones
Quinolones & Fluoroquinolones
 
Quinolone & Fluoroquinolones
 Quinolone & Fluoroquinolones Quinolone & Fluoroquinolones
Quinolone & Fluoroquinolones
 
Quinolones &UTI
Quinolones &UTIQuinolones &UTI
Quinolones &UTI
 

Viewers also liked (7)

Quinolones
QuinolonesQuinolones
Quinolones
 
Quinolones
QuinolonesQuinolones
Quinolones
 
Ciprofloxacin ppt
Ciprofloxacin pptCiprofloxacin ppt
Ciprofloxacin ppt
 
ciprofloxacin
ciprofloxacinciprofloxacin
ciprofloxacin
 
Fluoroquinolones 12 mins
Fluoroquinolones 12 minsFluoroquinolones 12 mins
Fluoroquinolones 12 mins
 
Antibiotics Groups - Quinolones
Antibiotics Groups - QuinolonesAntibiotics Groups - Quinolones
Antibiotics Groups - Quinolones
 
Quinolones | drug develoupment | mechanism of action | future
Quinolones | drug develoupment | mechanism of action | futureQuinolones | drug develoupment | mechanism of action | future
Quinolones | drug develoupment | mechanism of action | future
 

Similar to Fluoroquinolones

Presentation2 copy.pptx
Presentation2 copy.pptxPresentation2 copy.pptx
Presentation2 copy.pptx
ShadKawa
 
Antibiotics course quinolones
Antibiotics course quinolonesAntibiotics course quinolones
Antibiotics course quinolones
mohamednassar1
 

Similar to Fluoroquinolones (20)

Anti leprotic drugs
Anti leprotic drugsAnti leprotic drugs
Anti leprotic drugs
 
Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.
Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.
Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.
 
Quinolones & fluoroquinolones
Quinolones & fluoroquinolonesQuinolones & fluoroquinolones
Quinolones & fluoroquinolones
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolones
 
Quinolones and fluroquinolones
Quinolones and fluroquinolonesQuinolones and fluroquinolones
Quinolones and fluroquinolones
 
Presentation2 copy.pptx
Presentation2 copy.pptxPresentation2 copy.pptx
Presentation2 copy.pptx
 
Chemotherapy
ChemotherapyChemotherapy
Chemotherapy
 
Quinolones
QuinolonesQuinolones
Quinolones
 
FLUOROQUINOLONES.pptx
FLUOROQUINOLONES.pptxFLUOROQUINOLONES.pptx
FLUOROQUINOLONES.pptx
 
Enteric fever
Enteric feverEnteric fever
Enteric fever
 
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptxCHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
 
Quinolones.pptx
Quinolones.pptxQuinolones.pptx
Quinolones.pptx
 
ANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGS  ANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGS
 
ANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGSANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGS
 
Quinolones and Fluoroquinolones
Quinolones and FluoroquinolonesQuinolones and Fluoroquinolones
Quinolones and Fluoroquinolones
 
Antimycobacterial drugs.ppt
Antimycobacterial drugs.pptAntimycobacterial drugs.ppt
Antimycobacterial drugs.ppt
 
Leprosy
LeprosyLeprosy
Leprosy
 
POWERPOINT PRESENTATION ON QUINOLINE
POWERPOINT PRESENTATION ON QUINOLINE  POWERPOINT PRESENTATION ON QUINOLINE
POWERPOINT PRESENTATION ON QUINOLINE
 
recent guidelines in treatment of malaria,anti malarial drugs 2014
recent guidelines in treatment of malaria,anti malarial drugs 2014recent guidelines in treatment of malaria,anti malarial drugs 2014
recent guidelines in treatment of malaria,anti malarial drugs 2014
 
Antibiotics course quinolones
Antibiotics course quinolonesAntibiotics course quinolones
Antibiotics course quinolones
 

Recently uploaded

Recently uploaded (20)

On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
Plant propagation: Sexual and Asexual propapagation.pptx
Plant propagation: Sexual and Asexual propapagation.pptxPlant propagation: Sexual and Asexual propapagation.pptx
Plant propagation: Sexual and Asexual propapagation.pptx
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 

Fluoroquinolones

  • 2. Classification (-floxacins)  First generation FQs o Norfloxacin o Ofloxacin o Pefloxacin o Ciprofloxacin Note: Remember as NOP Cipro  Second generation FQs o Levofloxacin o Lomefloxacin o Moxifloxacin o Gemifloxacin o Sparfloxacin Note: Remember as Levo Lome Moxi Gem Spark
  • 3. Mechanism of Action  The FQs enter the bacterium by passive diffusion through porins in the outer membrane  Once inside the cell, they inhibit replication of bacterial DNA by interfering with the action of DNA gyrase (Topoisomerase II) and Topoisomerase IV during bacterial growth and reproduction  Topoisomerases are the enzymes that change the configuration of DNA by a ‘nicking — pass through — resealing’ mechanism. They do not change the DNAs primary sequence
  • 4. Action of type II DNA Topoisomerase
  • 5. Mechanism of Action  Binding of quinolone to both the enzyme and the DNA forms a ternary complex that inhibits the resealing step, and can cause cell death by inducing the cleavage of the DNA  Because DNA gyrase is a bacteriospecific target for anti-microbial therapy, cross resistance with other, more commonly used anti-microbial drugs is rare, but this is increasing in the case of multi-drug resistant organisms  The second site blocked by FQs– Topoisomerase IV– is required by bacteria for cell division. It has been implicated in the process of
  • 6. In Gram-negative organisms (E. coli), the inhibition of DNA gyrase is more significant than that of Topoisomerase IV, whereas in Gram-positive organisms (Streptococci), the opposite is true.
  • 8. Uses  Urinary tract infections:  High cure rates, even in complicated cases or those with indwelling catheters or prostatitis  Chronic Pseudomonas infections respond less completely  Gonorrhoea:  Single dose of 500 mg was nearly 100% curative in PPNG as well as non-PPNG infections, but the cure rates have declined due to emergence of resistance and it is no longer a first line drug  Chanchroid:  500 mg BD for 3 days second line alternative drug to̶̶ Ceftriaxone/ Azithromycin
  • 9. Uses  Bacterial gastroenteritis:  Use is reserved for severe cases of diarrhoea due to EPEC, Shigella, Salmonella, Campylobacter jejuni infections  Can reduce stool volume in cholera  Typhoid:  One of the 1st choice drugs in typhoid fever  750 mg BD for 10 days is recommended or 200 mg i.v 12 hourly till oral therapy can be instituted  The advantages of Ciprofloxacin are: o quick defervescence: fever usually subsides in 4-5 days o Early abetment of symptoms, low incidence of complications and relapse o Prevention of carrier state due to cidal action  Ciprofloxacin can be used to treat typhoid carrier (750 mg BD for 4-8 weeks). This has been found to achieve 92% eradication rate
  • 10. Uses  Bone, soft tissue, gynaecological and wound infections:  High cure rate have been obtained in osteomyelitis and joint infections but prolonged treatment with high doses (6-8 weeks with 750 md BD) is required  Respiratory infections:  Not a primary drug because Streptococci and Pneumococci have low susceptibility  However, RT infections due to Mycoplasma, Legionella, H.influenzae respond  Tuberculosis:  One of the drugs in multidrug regimens used for resistant TB  Also useful in atypical mycobacterial infections
  • 11. Uses  Gram negative septicaemias:  Parenteral Ciprofloxacin may be combined with 3rd generation cephalosporin or an aminoglycoside  Prophylaxis:  Prophylactic use for infections in neutropenic or cancer patients and other susceptible patients  Conjunctivitis:  Topical therapy is effective  Meningitis:  Though penetration in CSF is not very good, it has been successfully used in Gram negative bacterial meningitis especially that occuring in immunocompromised patients or those with CSF shunts
  • 12. Adverse effects Fluoroquinolones have good safety record: side effects occur in ~10% patients, but are generally mild, withdrawal needed only in 1.5%  GIT:  Nausea, vomiting, anorexia, bad taste  Does not affect gut anaerobes hence diarrhoea is infrequent̶  CNS:  Headache, dizziness, restlessness, anxiety, insomnia, impairment of concentration and dexterity  Tremor and seizures are rare: occur at high doses or when predisposing factors are present
  • 13. Adverse effects  Skin/hypersensitivity:  Rash, pruritus, photosensitivity, urticaria, swelling of lips etc.  Serious cutaneous reactions are rare  Tendinitis and tendon rupture:  Risk of tendon damage is higher in patients above 60 yrs age and in those receiving corticosteroids  FQs should be stopped at the first sign of tendinitis Contraindicated during pregnancy
  • 14. Abbreviations used  FQs- Fluoroquinolones  DNA- Deoxyribose Nucleic Acid  PPNG- Penicillinase Producing Neisseria Gonorrhoeae  BD- Twice daily  EPEC- Entero Pathogenic Escherichia Coli  RT- Respiratory Tract  TB- Tuberculosis  CSF- Cerebro Spinal Fluid  GIT- Gastro Intestinal Tract  CNS- Central Nervous System